亞寶藥業(600351.SH)擬0元受讓華方資產所持健民資本40.68%財產份額
格隆匯12月18日丨亞寶藥業(600351.SH)公佈,公司擬以0元人民幣受讓浙江華方資產管理有限公司(以下簡稱“華方資產”)持有的武漢健民資本合夥企業(有限合夥)(以下簡稱“健民資本”)40.68%的財產份額,對應認繳出資金額為1.2億元人民幣。
武漢健民資本合夥企業(有限合夥)主要投資於生物醫藥與大健康等戰略性新興產業,公司本次通過受讓武漢健民資本合夥企業(有限合夥)財產份額的方式參與其投資,有利於滿足公司在生物醫藥與大健康領域的拓展需求,符合公司現有及未來業務發展方向,有利於公司的長遠發展和戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.